More news articles

Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

Regulatory filings expected in first half of 2020

Roche preps filings for Herceptin/Perjeta combination

Potential defence against biosimilar competition

IQVIA and partners set up cancer ‘data hub’ to speed up research

Seven research centres to be rolled out across UK

Roche presents new data in NMOSD, could challenge Alexion's Soliris

Reduced risk of relapse by 55%

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

Gracell reports impressive data with one-day CAR-T for leukaemia

Takes fight to Novartis and Gilead

Sanofi exits Zynquista alliance with Lexicon

Will pay $260m to end collaboration

Democrats reveal pricing plan with 250-drug hit list

Listed drugs are costing Medicare the most each year

Mallinckrodt offloads CDMO for $250m

Move follows US opioid settlement

Merck takes evobrutinib for MS into phase 3, on mixed data

First drug in class to reach this stage for the illness

Novartis’ CAR-T Kymriah scores SMC approval

Will now be available on NHS across the UK

Boehringer bags FDA OK for Ofev in rare lung disease ILD

First drug approved for condition

Prescription drug dependence 'linked to deprivation', says PHE

Public Health England publishes review on prescription rates

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

Amgen reveals more data on KRAS drug

Unveiled an overall disease control rate of 100%